Published in final edited form as:

Tetrahedron. 2008 July 14; 64(29): 6876–6883. doi:10.1016/j.tet.2008.04.023.

Multisubstituted N-fused heterocycles via transition metal-catalyzed cycloisomerization protocols

Ilya V. Seregin, Alex W. Schammel, and Vladimir Gevorgyan*

Department of Chemistry, University of Illinois at Chicago, 845 W. Taylor St., Chicago, Illinois 60607-7061

Abstract

Two complementary protocols for assembly of multisubstituted N-fused heterocycles have been developed. It was demonstrated that 1,3-disubstituted N-fused heterocycles, including indolizines, pyrroloquinoxalines, and pyrrolothiazoles can easily be synthesized via an exceptionally mild and efficient method involving a novel silver-catalyzed cycloisomerization of propargyl-containing heterocycles. Alternatively, 1,2-disubstituted heterocycles can be accessed through the novel cascade transformation involving an alkyne-vinylidene isomerization with concomitant 1,2-shift of hydrogen, silyl, stannyl, or germly groups. This mild and simple method allows for selective and highly efficient synthesis of indolizines, pyrroloisoquinolines, pyrroloquinoxalines, pyrrolopyrazines, and pyrrolothiazoles.

1. Introduction

Heteroaromatic molecules containing N-fused pyrrole unit, along with their partially or completely reduced analogues, are pharmaceutically significant scaffolds.^{i,ii} Structural fragments of this family are widely found in naturally occurring, as well as in synthetic biologically active molecules. Among diverse indolizine-containing biologically active molecules, the most prominent are: the potent topoisomerase I inhibitor, marine alkaloid Lamellarin D,^{iii,iv} the anti-HIV integrase agent, Lamellarin α 20-sulfate,^v 15-lipoxygenase^{vi} and sPLA2^{vii} inhibitors. More recently, the potent indolizine-containing cardiovascular agent^{viii} and anti-inflammatory CRTH2 receptor modulator^{ix} have also been reported. Although few routes toward fused pyrrole-heterocycles exist,^x there is a high demand for the effective and general methods for selective construction of heterocycles with alternative substitution pattern.

Recently, we reported two protocols for the synthesis of C-3 substituted and 1,3-disubstituted fused and non-fused pyrrole-containing heterocycles (eq. 1, 2). The first approach, which operates via a copper-assisted cycloisomerization of conjugated alkynyl imines (eq. 1), has been demonstrated to be very general and efficient for synthesis of C-3 monosubstituted heterocycles. This method, however, is not applicable for synthesis of C-2- and/or C-3-substituted heterocycles.^{xi} We also disclosed a set of cycloisomerization methodologies of imines and alkynyl ketones with concomitant acyloxy, phosphatyloxy, or sulfonyloxy group

© 2008 Elsevier Science. All rights reserved

*Corresponding author. Tel.: +1-312-355-3579; fax: +1-312-355-0836; e-mail: E-mail: vlad@uic.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

migration, which allows for the efficient synthesis of 1,3-disubstituted indolizines and other heterocycles (eq. 2).^{xii}

Aiming at the development of alternative methods toward heterocyclic units with different substitution pattern, as well as at the expanding the scope of heterocyclic cores, we have developed two complementary protocols for cycloisomerization of propargyl-containing heterocycles (eq. 3). These methods, being mild and effective, allow for selective preparation of 1,3- or 1,2-disubstituted N-fused heterocycles. We demonstrated, that in the presence of Ag, Cu or Au catalyst, 2-propargyl pyridines, quinoxalines, and thiazoles undergo smooth and facile cycloisomerization resulting in 1,3-disubstituted indolizines, pyrroloquinoxalines, and pyrrolothiazoles, in good to excellent yields.^{xiii,xiv} In addition, we showed that 1,2-disubstituted heterocycles can be accessed via a novel alkyne-vinylidene isomerization cascade with concomitant 1,2-shift of various groups such as H, SiR₃, SnR₃, and even previously unknown migration of germyl group, and allows for the efficient synthesis of various fused pyrroloheterocycles functionalized at C-2 (eq 3).^{xv} Herein, we summarize our recent developments in this area, and provide a more detailed discussion of the scope and mechanisms of these novel transformations.

2. Results and discussion

2.1. Mild cycloisomerization of propargylic heterocycles

We anticipated that the triple bond of a propargyl-substituted heterocycle may be rendered reactive toward intramolecular nucleophilic attack of heterocyclic nitrogen by coordination of a π -philic metal, such as Cu, Ag, or Au. First, we tested easily available propargylic derivative of pyridine **1a** under the previously elaborated copper/base-promoted cyclo-isomerization conditions.^{xi} It was found that **1a** underwent smooth cycloisomerization furnishing indolizine

2a in good yield. Notably, the cycloisomerization of “skipped” propargyl pyridine **1a** did not require elevated temperatures, as it was necessary for cycloisomerization of the conjugated substrates (eq. 1). Thus, we were able to obtain **2** in good yield performing reaction at room temperature. Moreover, we found, that base is not required for this transformation, hence, it can be omitted, as well as dimethylacetamide solvent can be substituted with easier to handle dichloromethane. At the same time, the catalyst load was dropped from 30 to 3 mol%. Employment of Cu(I) salts under these conditions resulted in a very facile conversion of **1a**, both copper iodide and chloride led to high yields of **2a**, affording 77% and 83% yields, respectively (Table 1). Gold catalysts were found to be efficient in this transformation, as well. Thus, Au(I) iodide and Au(III) chloride furnished **2a** in 71% and 95% yields, respectively, though the reaction was substantially slower. Contrary, only moderate yields of **2a** were obtained in the presence of other metals, such as Al, Sn, In, Mg, Pt, and Pd (Table 1). Recently, several reports appeared, which debated the role of eventual Brønsted acid as the true catalyst in transition metal-catalyzed transformations.^{xvi} To address this issue, we tested this reaction in the presence of triflic acid, and found that only negligible amounts of **2a** were produced (entry 15). In contrast, switching to AgBF₄ and AgPF₆ led to virtually quantitative yields of **2a** (entries 12, 13)!

The approach toward propargyl-substituted heterocycles **1**, including **1a** employed in our initial optimization, is general for all substrates (Scheme 1). This two-step procedure proved to be more efficient compared to the same sequence of steps performed in “on-pot”. It was found, that upon column purification on silica gel, propargyl alcohols **1'** undergo facile isomerization into α,β -unsaturated ketons (eq. 4),^{xvii} therefore, compounds **1'** were used without additional purification in the next step. In a typical procedure, heterocyclic aldehydes were treated with magnesium acetylides to afford the corresponding propargyl alcohols **1'** which were further converted to acetyloxy-, phosphatyloxy-, or silyloxy-containing compounds **1** in good to very high yields (Scheme 1).

Next, the scope of this cycloisomerization has been examined. To this end, a series of propargyl-substituted heterocycles **1a–l** were synthesized and tested under the optimized conditions (Scheme 2). We were pleased to find, that acetyloxy, diethylphosphatyloxy-, and O-TBS-protected propargylic substrates **1a–k**, possessing alkyl (**1b**, **1j**, **1l**, **1h**), aryl (**1a**, **1e**, **1i**), heteroaryl (**1k**), and alkenyl (**1c**, **1g**) substituents at the triple bond, as well as those possessing terminal alkyne moiety (**1f**, **1d**), underwent smooth cycloisomerization to give corresponding heterocycles **2a–k** in good to excellent yields (Scheme 2). In contrast, diyne-containing substrate **1l** furnished pyrrolothiazole **2l** in a very moderate yield. Of note, alkynyl N-fused heterocycles can be alternatively accessed *via* the recently developed direct C–H alkynylation approach.^{xviii} Further, the scope of this cycloisomerization with regard to the heterocyclic core was examined. It was found that disubstituted indolizines (**2a–f**), pyrroloquinoxalines (**2g**, **2h**) and pyrrolothiazoles (**2i–k**) can also be synthesized through this cycloisomerization in preparative yields (Scheme 2).

We propose the following mechanistic rationale for this novel cycloisomerization (Scheme 3). First, an intramolecular nucleophilic attack of the heterocyclic nitrogen^{xix} at the metal-activated-triple bond takes place (**3**) to produce zwitter-ionic adduct **4**, which then rearomatizes into the product **6** (Scheme 3). The rearomatization may proceed *via* two alternative pathways: through a proton transfer sequence (Path **A**), or by a hydride shift (Path **B**). In the deprotonation-protonation scenario, heterocyclic nitrogen of **3** would play a role of the base, as no other base present in the reaction. Accordingly, we reasoned that if a deprotonation-protonation event,

indeed, takes place (Path **A**), a severe deuterium-hydrogen exchange in isotope-labeled substrate would be observed.^{xx} Conversely, if a hydride shift is the key step of the rearomatization (Path **B**), a clean deuterium incorporation at C-2 of the product **6** would be expected.^{xxi} To address this question, a deuterium-labeled propargyl pyridine **7** was subjected to the cycloisomerization conditions (eq. 5).^{xxii} A substantial proton-deuterium exchange (c.a. 50%) was observed. It is believed that this observation strongly supports the deprotonation-protonation pathway **A**. Obviously, Path **B** is in a contradiction with this result (Scheme 3).

2.2. Gold-catalyzed cascade 1,2-migration/cycloisomerization

Encouraged by the successful development of cycloisomerization toward 1,3-disubstituted N-fused ring systems, we reasoned that propargylic heterocycles can serve as precursors for 1,2-disubstituted products as well, if *migratory* cycloisomerization^{xii} is achieved. Thus, we turned our attention to the development of an alternative cycloisomerization protocol, which would allow for a complementary substitution pattern at the fused pyrrole ring. Particularly, alkyne-vinylidene isomerization has drawn our attention. This rearrangement has long been recognized as a synthetically useful^{xxiii} and mechanistically interesting^{xxiv} transformation. In elegant series of works, McDonald employed this transformation as the key step in the efficient synthesis of oxygen, nitrogen, and sulfur-containing heterocycles, as well as in the synthesis of carbocycles (eq 6).^{xxv} Moreover, it was exemplified by a number of research groups, that a 1,2-migration of certain groups can occur upon alkyne-vinylidene isomerization. For instance, Iwasawa^{xxvi} and Fürstner^{xxvii} have shown that halogens undergo 1,2 shift in the presense of tungsten and gold complexes. Furthermore, Katayama demonstrated the Ru-catalyzed migration of silicon,^{xxviii} and Kawakami^{xxix} reported an analogous transformation with trialkyl tin (eq 7). Hence, we reasoned, that alkyne-vinylidene isomerization with a concurrent 1,2-shift of the groups other than hydrogen, can potentially be employed in the synthesis of heterocycles, though no such examples have been reported.

First, we turned our attention to the cycloisomerization of easily available skipped propargylpyridine **9** (Scheme 4). Brief screening of transition metal catalysts revealed that **9**, in the presence of Au(I) or Au(III) catalyst,^{xxx} underwent smooth cycloisomerization into C-1 mono-substituted indolizine **10**.^{xxxi} It is reasonable to propose that this transformation may operate through diverse mechanistic pathways: *via* a zwitterionic intermediate **i**, similar to **4** (Scheme 1),^{xiii} or, alternatively, through an allenyl intermediate **v**, resulting from the formal 1,3-hydride shift.^{xi} Finally, the reaction may proceed via the gold-vinylidene intermediate **iv** (Scheme 4).

In order to elucidate if this reaction, indeed, can proceed *via* a vinylidene intermediate **iv**, we examined cycloisomerization of TMS-substituted propargylpyridine **11a** in the presence of Au-catalyst. A prototropic isomerization through intermediate **v**,^{xxxi} as well as formation of a zwitter-ionic intermediate **i**, would result in the formation of C-3-silyl indolizine, whereas

C-2-substituted isomer would be the expected product if the alkyne-vinylidene isomerization takes place. After initial experimentation, it was found that **11a** in the presence of AuBr₃ (2.0 mol %) in toluene at 50°C underwent smooth cycloisomerization to afford indolizine **12a** with TMS group residing at the C-2 as the sole regioisomer in 63% yield (eq. 8). Employment of Cu(I) salts led to trace amount of products, whereas various Ag, Pt, and Pd sources tested did not catalyzed this reaction at all. Of note, the C-2 position in indolizines, as well as in related fused heterocycles, has long been considered as “unfunctionalizable”, as a substituent generally has to be introduced prior to cyclization.^x

To examine the scope of this novel cascade migratory cycloisomerization, a series of substrates have been prepared (Scheme 5). Thus, H- and TMS-containing propargyl heterocycles were prepared using the protocol discussed above (Scheme 1). Whereas, stannyl and germly groups have been installed by deprotonation of the terminal alkynes **11'** furnishing lithium acetylides, which were quenched with stannyl and germly halides to form compounds **11b** and **11c**, respectively (Scheme 5).

Next, migratory cycloisomerization of **11a–j** in the presence of gold catalysts was examined. Thus, similarly to the silyl-containing substrate **11a**, its stannyl counterpart **11b** underwent smooth cycloisomerization to afford 2-stannyl indolizine **12b**.^{xxix} It was also found that previously unprecedented 1,2-migration of a germly group can occur: cyclization of the corresponding propargylic substrate **11c** furnished 2-germyl indolizine **12c** in excellent yield. It was also demonstrated that this protocol is efficient for construction of other related N-fused heterocyclic systems, such as pyrroloisoquinoline (**12e**), quinoxaline (**12f**, **12g**), pyrazine (**12h**, **12i**), and thiazole (**12j**). The corresponding substrates **11e–j** reacted smoothly, producing fused bicyclic and tricyclic molecules in good to excellent yields.

Additionally, this transformation was tested under catalyst-free conditions. It was found that in the absence of gold catalyst, propargylic substrate **13** at 60°C underwent thermal cycloisomerization into **14**, expectably, with no 1,2-silicon shift (eq. 9).

The mechanism of the gold-catalyzed cascade transformation can be rationalized as following (Scheme 7). First, alkyne **9** undergoes isomerization to form vinylidene intermediate **iv** (Scheme 4). A nucleophilic attack of the nitrogen lone pair at the vinylidene carbon results in the formation of zwitterion **15**, which can either undergo a sequence of 1,2-hydride shifts (Path A), or proton transfer processes (Path B), to give **12**. In order to verify which pathway operates, we examined cycloisomerization of deuterium-labelled propargyl pyridine **9-d**, under the

standard cycloisomerization conditions (eq. 10). The reaction produced indolizine **10-d** with equal distribution of deuterium between positions C-2 and C-3, thus strongly supporting Path **A** (Scheme 7).^{xxxiii} Logically, equal distribution of the deuterium between positions C-2 and C-3 is possible via the Path **A** if there is no H/D kinetic isotope effect in the transformation **16** to **12**. Obviously, Path **B** cannot explain the observed scrambling of deuterium at C-2.

Furthermore, we considered a possibility of Au-catalyzed 1,2-trimethylsilyl shift which may occur after cyclization.^{xxxiv} However, the test experiment with **14**, an isomer of pyrroloquinoxaline **12i**, ruled out this possibility (eq. 11).

3. Conclusions

Two complementary protocols for the preparation of multisubstituted N-fused heterocycles have been developed. It was demonstrated that 1,3- disubstituted N-fused heterocycles, including indolizines, pyrroloquinoxalines, and pyrrolothiazoles can be easily prepared via an exceptionally mild, and efficient method involving a novel silver-catalyzed cycloisomerization of propargyl-containing heterocycles. Alternatively, 1,2-disubstituted heterocycles can be accessed through the Au-catalyzed cascade cycloisomerization of propargylic derivatives of N-containing heterocycles into pyrrole-fused heterocycles. This cascade transformation involves 1,2-migration of silyl-, stannyl-, and germyl groups. This mild and simple method allows for selective and highly efficient synthesis of indolizines, pyrroloisoquinolines, pyrroloquinoxalines, pyrrolo-pyrazines, and pyrrolothiazoles, not available *via* existing cycloisomerization techniques.

4. Experimental

4.1. General

NMR spectra were recorded on Bruker Avance DRX-500 (500 MHz) and DPX-400 (400 MHz), instruments. GC/MS analyses were performed on a Hewlett Packard Model 6890 GC interfaced to a Hewlett Packard Model 5973 mass selective detector (15 m × 0.25 mm capillary column, HP-5MS). Column chromatography was carried out employing Silicycle silica gel (43–60 μm). HRMS (EI) analysis was performed on a JEOL GCmate II instrument. All manipulations with transition metal catalysts were conducted under inert atmosphere using a combination of glovebox and standard Schlenk techniques. Anhydrous toluene, tetrahydrofuran, and dichloromethane, purchased from Aldrich, were additionally purified on PureSolv PS-400-4 by Innovative Technology, Inc. purification system. All other chemicals and solvents were purchased from Aldrich, Fisher, Acros Organics, TCI, and Alfa Aesar and used without additional purification.

4.2. General procedures for Ag-catalyzed cycloisomerization

In a glovebox under nitrogen atmosphere, to a 5.0 mL Wheaton microreactor equipped with a spin vane and screw cap with a PTFE faced silicone septum was added 3–10 mol % of AgBF₄. The microreactor was removed from the glovebox, propargyl heterocycle **1a–II** and anhydrous toluene (0.10 M) were successively added and the mixture was stirred until completion (as monitored by TLC and/or GC/MS). The solvent was removed under reduced pressure and the residue was purified using flash-column chromatography using hexane or hexane/ethyl acetate mixture as eluent to afford pure fused pyrroloheterocycles **2a–2l**.

4.2.1. 1-(acetyloxy)-3-(phenyl)indolizine (2a)—¹H NMR (500.13 MHz, CDCl₃) δ ppm 8.18 (1 H, d, J=7.3 Hz), 7.56 (2 H, dd, J=8.3, 1.3 Hz), 7.44 – 7.50 (2 H, m), 7.32 – 7.37 (1 H, m), 7.29 (1 H, d, J=9.0 Hz), 6.83 (1 H, s), 6.65 (1 H, dd, J=9.2, 6.4 Hz), 6.44 (1 H, dd, J=8.4, 6.4 Hz), 2.37 (3 H, s); ¹³C NMR (125.76 MHz, CDCl₃) δ ppm 172.4, 131.8, 128.9, 128.1, 127.3, 123.0, 122.0, 121.6, 116.5, 116.3, 110.9, 109.5, 106.6, 20.9.

4.2.2. 1-(acetyloxy)-3-(hexyl)indolizine (2b)—¹H NMR (500.13 MHz, CDCl₃) δ ppm 7.61 (1 H, d, J=7.0 Hz), 7.22 (1 H, d, J=9.1 Hz), 6.56 (1 H, dd, J=9.1, 6.4 Hz), 6.53 (1 H, s), 6.45 (1 H, dd, J=8.5, 7.0 Hz), 2.76 (2 H, d, J=7.6 Hz), 2.34 (3 H, s), 1.66 – 1.79 (2 H, m), 1.37 – 1.49 (2 H, m), 1.29 – 1.37 (4 H, m), 0.90 (3 H, t, J=5.6 Hz); ¹³C NMR (125.76 MHz, CDCl₃) δ ppm 167.3, 121.5, 121.0, 120.9, 116.0, 114.8, 110.0, 110.0, 104.4, 31.6, 29.2, 27.1, 25.8, 22.6, 20.9, 14.1. HR EI MS m/z 259.1575, Calcd for C₁₆H₂₁NO₂ 259.1572.

4.2.3. 1-((t-butyl)dimethyl)silanyloxy)-3-(cyclohexenyl)-indolizine (2c)—¹H NMR (500.13 MHz, CDCl₃) δ ppm 8.03 (1 H, d, J=7.9 Hz), 7.24 (1 H, d, J=9.1 Hz), 6.35 (1 H, dd, J=8.9, 6.3 Hz), 6.27 (1 H, dd, J=7.0, 5.7 Hz), 6.03 (1 H, t, J=3.8 Hz), 2.29 – 2.38 (2 H, m), 2.20 – 2.30 (2 H, m), 1.75 – 1.85 (2 H, m), 1.65 – 1.75 (2 H, m), 1.02 (9 H, s), 0.19 (6 H, s); ¹³C NMR (125.76 MHz, CDCl₃) δ ppm 132.2, 128.9, 124.9, 122.5, 121.9, 120.8, 117.0, 112.7, 109.7, 103.3, 29.1, 25.8, 25.5, 23.0, 22.2, 18.2, –4.5. HR EI MS m/z 327.2010, Calcd for C₂₀H₂₉NOSi 327.2018.

4.2.4. 1-(diethylphosphatoxy)indolizine (2d)—¹H NMR (500.13 MHz, CDCl₃) δ ppm 7.72 (1 H, d, J=7.0 Hz), 7.39 (1 H, d, J=9.1 Hz), 7.06 (1 H, d, J=2.2 Hz), 6.69 (1 H, d, J=2.9 Hz), 6.58 (1 H, dd, J=9.4, 6.4 Hz), 6.38 (1 H, dd, J=8.5, 2.2 Hz), 4.21 (4 H, q, J=8.2 Hz), 1.34 (6 H, t, J=7.0 Hz); ¹³C NMR (125.76 MHz, CDCl₃) δ ppm 130.8, 128.8, 124.6, 116.2, 116.0, 110.4, 108.5, 105.2, 64.5, 16.1. HR EI MS m/z 269.0816, Calcd for C₁₂H₁₆NO₄P 269.0817.

4.2.5. 1-(diethylphosphatoxy)-3-(phenyl)indolizine (2e)—¹H NMR (500.13 MHz, Acetone-*d*₆) δ ppm 8.26 (1 H, d, J=7.3 Hz), 7.55 – 7.63 (2 H, m), 7.45 – 7.53 (3 H, m), 7.37 (1 H, d, J=6.5 Hz), 6.85 (1 H, s), 6.70 (1 H, dd, J=8.2, 7.3 Hz), 6.53 (1 H, dd, J=7.0, 6.4 Hz), 4.22 (4 H, q, J=4.0 Hz), 1.32 (6 H, t, J=7.0 Hz); ¹³C NMR (125.76 MHz, Acetone-*d*₆) δ ppm 131.6, 129.0, 127.8, 127.3, 121.5, 121.4, 116.4, 116.3, 111.2, 105.4, 105.4, 64.2, 64.1, 15.6, 15.6. HR EI MS m/z 345.1131, Calcd for C₁₈H₂₀NO₄P 345.1130.

4.2.6. 1-(acetyloxy)indolizine (2f)—¹H NMR (500.13 MHz, CDCl₃) δ ppm 7.75 (1 H, d, J=7.0 Hz), 7.22 (1 H, d, J=9.1 Hz), 7.14 (1 H, d, J=2.9 Hz), 6.72 (1 H, d, J=2.9 Hz), 6.60 (1 H, dd, J=9.1, 6.4 Hz), 6.41 (1 H, dd, J=7.0, 5.6 Hz), 2.34 (3 H, s); ¹³C NMR (125.76 MHz, CDCl₃) δ ppm 169.5, 124.8, 116.4, 115.9, 115.7, 110.4, 110.1, 109.0, 106.3, 20.9. HR EI MS m/z 175.0634, Calcd for C₁₀H₉NO₂ 175.0633.

4.2.7. 1-(cyclohexenyl)-3-((t-butyl)dimethyl)silanyloxy)-pyrrolo[1,2]quinoxaline (2g)—¹H NMR (500.13 MHz, CDCl₃) δ ppm 8.63 (1 H, s), 7.97 (1 H, d, J=4.7 Hz), 7.82 (1 H, d, J=5.0 Hz), 7.28 – 7.38 (2 H, m), 6.10 (1 H, s), 5.99 – 6.08 (1 H, m), 2.17 – 2.34 (3 H, m),

1.68 – 1.90 (5 H, m), 1.03 (9 H, s), 0.25 (6 H, s); ^{13}C NMR (125.76 MHz, CDCl_3) δ ppm 143.7, 139.5, 137.4, 131.9, 131.8, 130.7, 129.2, 129.1, 126.3, 124.4, 116.6, 116.1, 109.5, 105.7, 28.9, 25.6, 25.5, 22.5, 21.7, 18.2, –4.5. HR EI MS m/z 378.2125, Calcd for $\text{C}_{23}\text{H}_{30}\text{N}_2\text{OSi}$ 378.2127.

4.2.8. 1-(hexyl)-3-(acetyloxy)-pyrrolo[1,2]-quinoxaline (2h)— ^1H NMR (500.13 MHz, CDCl_3) δ ppm 8.65 (1 H, s), 8.08 (1 H, d, $J=8.2$ Hz), 7.92 (1 H, d, $J=7.6$ Hz), 7.35 – 7.53 (2 H, m), 6.68 (1 H, s), 3.08 – 3.33 (2 H, m), 2.39 (3 H, s), 1.72 – 1.95 (2 H, m), 1.43 – 1.60 (2 H, m), 1.27 – 1.44 (4 H, m), 0.91 (3 H, t, $J=7.02$ Hz); ^{13}C NMR (125.76 MHz, CDCl_3) δ ppm 168.6, 142.8, 137.5, 132.8, 131.6, 130.1, 129.4, 127.0, 124.9, 116.6, 116.1, 106.4, 31.6, 30.8, 29.1, 28.1, 22.5, 21.0, 14.0. HR EI MS m/z 310.1693, Calcd for $\text{C}_{19}\text{H}_{22}\text{N}_2\text{O}_2$ 310.1681.

4.2.9. 5-(phenyl)-7-(acetyloxy)pyrrolo[1,2]thiazole (2i)— ^1H NMR (500.13 MHz, CDCl_3) δ ppm 7.63 (1 H, d, $J=4.2$ Hz), 7.45 – 7.50 (2 H, m), 7.39 – 7.45 (2 H, m), 7.24 – 7.32 (1 H, m), 6.63 (1 H, d, $J=4.2$ Hz), 6.54 (1 H, s), 2.31 (3 H, s); ^{13}C NMR (125.76 MHz, CDCl_3) δ ppm 168.1, 132.4, 128.9, 126.7, 126.2, 122.5, 119.2, 119.0, 119.0, 112.3, 105.4, 20.8. HR EI MS m/z 257.0500, Calcd for $\text{C}_{14}\text{H}_{11}\text{NO}_2\text{S}$ 257.0511.

4.2.10. 5-(hexyl)-7-(acetyloxy)pyrrolo[1,2]thiazole (2j)— ^1H NMR (500.13 MHz, CDCl_3) δ ppm 7.16 (1 H, d, $J=4.2$ Hz), 6.54 (1 H, d, $J=4.2$ Hz), 6.11 (1 H, s), 2.58 – 2.72 (2 H, m), 2.26 (3 H, s), 1.57 – 1.67 (2 H, m), 1.34 – 1.42 (2 H, m), 1.26 – 1.34 (2 H, m), 0.89 (3 H, t, $J=6.9$ Hz); ^{13}C NMR (125.76 MHz, CDCl_3) δ ppm 168.2, 127.7, 121.9, 117.7, 115.3, 111.3, 103.7, 31.6, 28.9, 28.3, 26.8, 22.6, 20.8, 14.1. HR EI MS m/z 265.1130, Calcd for $\text{C}_{14}\text{H}_{19}\text{NO}_2\text{S}$ 265.1137.

4.2.11. 5-(3-pyridyl)-7-((t-butylidimethyl)silanyloxy)-pyrrolo[1,2]thiazole (2k)— ^1H NMR (500.13 MHz, CDCl_3) δ ppm 8.74 (1 H, s), 8.44 (1 H, d, $J=3.7$ Hz), 7.73 (1 H, d, $J=7.9$ Hz), 7.58 (1 H, d, $J=4.2$ Hz), 7.31 (1 H, dd, $J=7.8$, 4.9 Hz), 6.64 (1 H, d, $J=3.5$ Hz), 6.35 (1 H, s), 1.01 (9 H, s), 0.23 (6 H, s); ^{13}C NMR (125.76 MHz, CDCl_3) δ ppm 146.6, 146.4, 134.2, 132.4, 129.1, 123.7, 118.8, 118.4, 118.1, 111.8, 106.6, 25.7, 18.1, –4.4. HR EI MS m/z 324.1660, Calcd for $\text{C}_{19}\text{H}_{24}\text{N}_2\text{OSi}$ 324.1658.

4.3. General procedures for Au-catalyzed cycloisomerization

In a glovebox under nitrogen atmosphere, to a 3.0 mL Wheaton microreactor equipped with a spin vane and screw cap with a PTFE faced silicone septum was added 2 mol % of AuBr_3 . The microreactor was removed from the glovebox, propargylic heterocycle **9** or **11a–j** and anhydrous toluene (0.5M) were successively added and the mixture was stirred until completion (as monitored by TLC and/or GC/MS). The solvent was removed under reduced pressure and the residue was purified using flash-column chromatography using hexane as eluent to afford pure fused pyrroloheterocycles **10**, **12a–j**.

4.3.1. 1-((t-butylidimethyl)silanyloxy)indolizine (10)—Prepared in 62% yield. ^1H NMR (500.13 MHz, acetone- d_6) δ 7.87 (1H, d, $J=7.0$ Hz), 7.24 (1H, d, $J=9.2$ Hz), 7.17 (1H, d, $J=1.8$ Hz), 6.42 (1H, dd, $J=9.0$, 6.4 Hz), 6.36 (1H, d, $J=2.6$ Hz), 6.29 (1H, dd, $J=6.7$, 6.7 Hz), 1.04 (9H, s), 0.20 (6H, s). ^{13}C NMR (125.76 MHz, acetone- d_6) δ 133.1, 126.3, 122.7, 117.9, 115.1, 111.0, 109.6, 106.1, 26.9, 19.4, –3.7. HRMS (EI) calcd. for $\text{C}_{14}\text{H}_{21}\text{NOSi}$ $[M+]$: 247.1392. Found: 247.1392.

4.3.2. 1-(t-butylidimethyl)silanyloxy-2-(trimethylsilyl) indolizine (12a)—Prepared in 63% yield for 2 steps, ^1H NMR (500.13 MHz, acetone- d_6) δ 7.84 (1H, d, $J=7.2$ Hz), 7.23 (1H, d, $J=9.9$ Hz), 7.17 (1H, s), 6.39 (1H, dd, $J=10.2$, 6.3 Hz), 6.25 (1H, dd, $J=7.3$, 6.2 Hz), 1.09 (9H, s), 0.32 (9H, s), 0.22 (6H, s); ^{13}C NMR (125.76 MHz, acetone- d_6) δ 137.1, 125.4, 122.2,

117.7, 115.1, 114.4, 110.2, 26.4, 18.8, 0.4, -3.1. HRMS (EI) calcd. for $C_{17}H_{29}NOSi_2$ [M⁺]: 319.1788. Found: 319.1782.

4.3.3. 1-(*t*-butyldimethyl)silanyloxy-2-(tributylstannyl) indolizine (12b)—Prepared in 64% for 2 steps (by NMR), 1H NMR (500.13 MHz, benzene- d_6) δ 7.36 (1H, d, $J=9.0$ Hz), 7.08 (1H, d, $J=7.0$ Hz), 6.80 (1H, s), 6.22 (1H, dd, $J=9.5$, 6.8 Hz), 5.90 (1H, dd, $J=7.5$, 6.4 Hz), 1.67 – 1.79 (6H, m), 1.42 – 1.51 (6H, m), 1.25 – 1.32 (6H, m), 1.14 (9H, s), 0.93 – 1.01 (9H, m), 0.21 (6H, s); ^{13}C NMR (125.76 MHz, benzene- d_6) δ 124.2, 117.2, 115.5, 114.4, 113.5, 109.2, 29.7, 27.8, 26.2, 18.4, 13.9, 10.5, 2.1, -3.7. MS m/z (relative intensity) 537 (M⁺, 84), 480 (M⁺ - *t*Bu, 80), 368 (M⁺ - 3*n*Bu, 210); $C_{26}H_{47}NOSiSn$.

4.3.4. 1-(*t*-butyldimethyl)silanyloxy-2-(trimethylgermyl) indolizine (12c)—Prepared in 92%, 0.75 mmol, 1H NMR (500.13 MHz, acetone- d_6) δ 7.85 (1H, d, $J=7.0$ Hz), 7.22 (1H, d, $J=9.1$ Hz), 7.12 (1H, s), 6.40 (1H, dd, $J=9.1$, 6.4 Hz), 6.25 (1H, dd, $J=7.2$, 6.4 Hz), 1.08 (9H, s), 0.44 (9H, s), 0.20 (6H, s); ^{13}C NMR (125.76 MHz, acetone- d_6) δ 129.8, 125.5, 122.5, 117.7, 114.5, 114.0, 110.1, 105.6, 26.6, 0.1, -3.2. HRMS (EI) calcd. for $C_{17}H_{29}GeNOSi$ [M⁺]: 365.1230. Found: 365.1244.

4.3.5. 1-(*t*-butyldimethyl)-silanyloxy-5-bromo-indolizine (12d)—Prepared in 62%, 1H NMR (500.13 MHz, $CDCl_3$) δ 7.31 (1H, d, $J=9.9$ Hz), 7.28 (1H, d, $J=2.3$ Hz), 6.64 (1H, d, $J=6.8$ Hz), 6.46 (1H, d, $J=2.9$ Hz), 6.34 (1H, dd, $J=8.9$, 6.9 Hz), 1.03 (9H, s), 0.20 (6H, s); ^{13}C NMR (125.76 MHz, $CDCl_3$) δ 133.6, 123.7, 115.7, 114.2, 113.7, 113.4, 108.8, 105.4, 25.7, 18.1, -4.6. HRMS (EI) calcd. for $C_{14}H_{20}BrNOSi$ [M⁺]: 325.0498. Found: 325.0501.

4.3.6. 1-((*t*-butyldimethyl)silanyloxy)pyrrolo[2,1-*a*]-isoquinoline (12e)—Prepared in 81% yield, 1H NMR (500.13 MHz, $CDCl_3$) δ 8.45 (1H, d, $J=8.07$ Hz), 7.46 (1H, d, $J=7.3$ Hz), 7.44 (1H, dd, $J=10.7$, 8.0 Hz), 7.42 (1H, dd, $J=11.0$, 8.3 Hz), 7.23 (1H, d, 5.0 Hz), 6.95 (1H, d, $J=2.9$ Hz), 6.50 (1H, d, $J=7.3$ Hz), 6.31 (1H, d, $J=2.9$ Hz), 1.10 (9H, s), 0.30 (6H, s); ^{13}C NMR (125.76 MHz, $CDCl_3$) δ 136.8, 127.5, 127.1, 126.6, 126.3, 124.8, 124.4, 122.4, 115.9, 110.6, 110.5, 103.9, 26.2, 18.5, -3.9. HRMS (EI) calcd. for $C_{18}H_{23}NOSi$ [M⁺]: 297.1549. Found: 297.1536.

4.3.7. 3-((*t*-butyldimethyl)-silanyloxy)pyrrolo[1,2]quinoxaline (12f)—Prepared in 94% yield, 1H NMR (500.13 MHz, $CDCl_3$) δ 8.68 (1H, s), 7.83 (1H, d, $J=7.9$ Hz), 7.7 (5H, d, $J=8.0$ Hz), 7.58 (5H, d, $J=2.9$ Hz), 7.38 (1H, dd, $J=8.0$, 1.6 Hz), 7.34 (1H, dd, $J=7.9$, 1.5 Hz), 6.32 (1H, d, $J=2.9$ Hz), 1.02 (9H, s), 0.22 (6H, s). ^{13}C NMR (125.76 MHz, $CDCl_3$) δ 143.6, 139.7, 136.1, 129.7, 127.6, 127.2, 124.8, 116.0, 112.8, 110.8, 109.4, 104.6, 25.6, 18.2, -4.7. HRMS (EI) calcd. for $C_{17}H_{22}N_2OSi$ [M⁺]: 298.1501. Found: 298.1503.

4.3.8. 2-(trimethylsilyl)-3-((*t*-butyldimethyl)silanyloxy)-pyrrolo[1,2]quinoxaline (12g)—Prepared in 78% yield, 1H NMR (500.13 MHz, $CDCl_3$) δ 8.69 (1H, s), 7.82 (1H, d, $J=7.7$ Hz), 7.75 (1H, d, $J=8.3$ Hz), 7.60 (1H, s), 7.44 (1H, d, $J=8.1$ Hz), 7.36 (1H, d, $J=8.0$ Hz), 7.26 (1H, s), 1.09 (9H, s), 0.35 (9H, s), 0.27 (6H, s). ^{13}C NMR (125.76 MHz, $CDCl_3$) δ 144.7, 144.4, 136.1, 129.8, 127.8, 127.6, 125.2, 117.0, 116.8, 115.1, 113.1, 26.2, 25.9, 0.2, -3.3. HRMS (EI) calcd. for $C_{20}H_{30}N_2OSi_2$ [M⁺]: 370.1897. Found: 370.1893.

4.3.9. 8-((*t*-butyldimethyl)silanyloxy)pyrrolo[1,2]pyrazine (12h)—Prepared in 72% yield, 1H NMR (500.13 MHz, $CDCl_3$) δ 8.64 (1H, s), 7.47 (1H, d, $J=5.0$ Hz), 7.23 (1H, d, $J=5.0$ Hz), 7.07 (1H, d, $J=2.8$ Hz), 6.30 (1H, d, $J=2.6$ Hz), 0.99 (9H, s), 0.18 (6H, s). ^{13}C NMR (125.76 MHz, $CDCl_3$) δ 143.6, 136.5, 126.7, 118.5, 117.4, 111.1, 105.1, 25.9, 18.3, -4.5. HRMS (EI) calcd. for $C_{13}H_{20}N_2OSi$ [M⁺]: 248.1345. Found: 248.1347.

4.3.10. 7-(trimethylsilyl)-8-((t-butyl)dimethyl)silanyloxy)-pyrrolo[1,2]pyrazine (12i)—Prepared in 87% yield, ^1H NMR (500.13 MHz, CDCl_3) δ 8.63 (1H, s), 7.46 (1H, d, $J=5.0$ Hz), 7.18 (3H, d, $J=5.0$ Hz), 7.06 (1H, s), 1.05 (9H, s), 0.30 (9H, s), 0.23 (6H, s). ^{13}C NMR (125.76 MHz, CDCl_3) δ 144.0, 140.8, 126.2, 118.7, 117.0, 116.6, 115.2, 25.9, 18.3, -0.1 , -3.6 . HRMS (EI) calcd. for $\text{C}_{16}\text{H}_{28}\text{N}_2\text{OSi}_2$ $[\text{M}^+]$: 320.1740. Found: 320.1741.

4.3.11. 6-(trimethylsilyl)-7-((t-butyl)dimethyl)silanyloxy)-pyrrolo[1,2]thiazole, (12j)—Prepared in 56% yield, ^1H NMR (500.13 MHz, CDCl_3) δ 7.11 (1H, d, $J=4.2$ Hz), 6.86 (1H, s), 6.44 (1H, d, $J=4.2$ Hz), 1.02 (9H, s), 0.27 (6H, s), 0.26 (9H, s). ^{13}C NMR (125.76 MHz, CDCl_3) δ 137.2, 119.5, 117.1, 113.4, 112.3, 110.6, 25.9, 25.7, 18.0, -0.2 , -3.4 . HRMS (EI) calcd. for $\text{C}_{15}\text{H}_{27}\text{NOSSi}_2$ $[\text{M}^+]$: 325.1352. Found: 325.1347.

Acknowledgments

The support of the National Institutes of Health (Grant GM-64444) and National Science Foundation (Grant CHE 0354613) is gratefully acknowledged.

References

- i. For review, see: Michael JP. *Nat. Prod. Rep* 1999;16:675.
- ii. For pharmacologically important indolizines, see, (a) Schoeffter P, Hoyer D. *Naunyn-Schmiedeberg's Arch. Pharmacol* 1989;339:675. (b) Fujita T, Matsumoto Y, Kimura T, Yokota S, Sawada M, Majima M, Ohtani Y, Kumagai Y. *Br. J. Clin. Pharmacol* 2002;54:283. [PubMed: 12236849] (c) Nakayama O, Hirosumi J, Chida N, Takahashi S, Sawada K, Kojo H, Notsu Y. *Prostate* 1997;31:241. [PubMed: 9180934]
- iii. Facompre M, Tardy C, Bal-Mahieu C, Colson P, Perez C, Manzanares I, Cuevas C, Bailly C. *Cancer Res* 2003;63:7392. [PubMed: 14612538]
- iv. For studies on biological activity of Lamellarin family, see: (a) Facompre M, Tardy C, Bal-Mahieu C, Colson P, Perez C, Manzanares I, Cuevas C, Bailly C. *Cancer Res* 2003;63:7392. [PubMed: 14612538] (b) Reddy MV, Rao MR, Rhodes D, Hansen MS, Rubins K, Bushman FD, Venkateswarlu Y, Faulkner DJ. *J. Med. Chem* 1999;42:1901. [PubMed: 10354398] (c) Østby OB, Dalhus B, Gundersen L-L, Rise F, Bast A, Haenen GRMM. *Eur. J. Org. Chem* 2000:3763.
- v. Reddy MV, Rao MR, Rhodes D, Hansen MS, Rubins K, Bushman FD, Venkateswarlu Y, Faulkner DJ. *J. Med. Chem* 1999;42:1901. [PubMed: 10354398]
- vi. (a) Gundersen L-L, Malterud KE, Negussie AH, Rise F, Teklu S, Østby OB. *Bioorg. Med. Chem* 2003;11:5409. [PubMed: 14642585] (b) Teklu S, Gundersen L-L, Larsen T, Malterud KE, Rise F. *Bioorg. Med. Chem* 2005;13:3127. [PubMed: 15809148]
- vii. Hagishita S, Yamada M, Shirahase K, Okada T, Murakami Y, Ito Y, Matsuura T, Wada M, Kato T, Ueno M, Chikazawa Y, Yamada K, Ono T, Teshirogi I, Ohtani M. *J. Med. Chem* 1996;39:3636. [PubMed: 8809154]
- viii. Gautier P, Marchionni D, Roccon A, Tonnerre B, Wagnon J. 2007FR 2893616
- ix. For studies on sPLA₂ inhibition activity, see: Hagishita S, Yamada M, Shirahase K, Okada T, Murakami Y, Ito Y, Matsuura T, Wada M, Kato T, Ueno M, Chikazawa Y, Yamada K, Ono T, Teshirogi I, Ohtani M. *J. Med. Chem* 1996;39:3636. [PubMed: 8809154]
- x. For the most comprehensive review, see: (a) Behnisch A, Behnisch P, Eggenweiler M, Wallenhorst T. *Indolizine. Houben-Weyl* 1994;Vol. E6b/1, 2aStuttgart, GermanyThieme:323–450.450 See also: (b) Marchalin S, Baumlova B, Baran P, Oulyadi H, Daich A. *J. Org. Chem* 2006;71:9114. [PubMed: 17109537] (c) Kaloko J Jr, Hayford A. *Org. Lett* 2005;7:4305. [PubMed: 16146413]
- xi. (a) Kel'in AV, Sromek AW, Gevorgyan V. *J. Am. Chem. Soc* 2001;123:2074. [PubMed: 11456838] (b) Kel'in AV, Gevorgyan V. *J. Org. Chem* 2002;67:95. [PubMed: 11777444]
- xii. (a) Sromek AW, Kel'in AV, Gevorgyan V. *Angew. Chem., Int. Ed* 2004;43:2280. (b) Schwier T, Sromek AW, Yap DML, Chernyak D, Gevorgyan V. *J. Am. Chem. Soc* 2007;129:9868. [PubMed: 17658805] For other syntheses of heterocycles proceeding via 1,2 migrations, see: (a) Kim JT, Kel'in AV, Gevorgyan V. *Angew. Chem., Int. Ed* 2003;42:98. (b) Dudnik AS, Gevorgyan V. *Angew.*

- Chem. Int. Ed 2007;46:5195. (c)Dudnik AS, Sromek AW, Rubina M, Kim JT, Kel'in AV, Gevorgyan V. J. Am. Chem. Soc 2008;130:1440. [PubMed: 18173272]
- xiii. Seregin IV, Schammel AW, Gevorgyan V. Org. Lett 2007;9:3433. [PubMed: 17637023]
- xiv. When this project was underway, a report on a related Pt-catalyzed 1,2-migration/cyclization toward indolizine core appeared, see: Smith CR, Bunnelle EM, Rhodes AJ, Sarpong R. Org. Lett 2007;9:1169. [PubMed: 17309277]
- xv. Seregin IV, Gevorgyan V. J. Am. Chem. Soc 2006;128:12050. [PubMed: 16967938]
- xvi. For recent discussions on the role of Brønsted acids in transition metal-catalyzed transformations, see: (a)Hashmi ASK. Catal. Today 2007;122:211. (b)Li Z, Zhang J, Brouwer C, Yang C-G, Reich NW, He C. Org. Lett 2006;8:4175. [PubMed: 16956180] (c)Rosenfeld DC, Shekhar S, Takemiya A, Utsunomiya M, Hartwig JF. Org. Lett 2006;8:4179. [PubMed: 16956181] (d)Rhee JU, Krische MJ. Org. Lett 2005;7:2493. [PubMed: 15932231]
- xvii. For acid-promoted isomerization of propargylic alcohols into α,β -unsaturated systems, see: Erenler R, Biellmann J-F. Tetrahedron Lett 2005;46:5683.
- xviii. Seregin IV, Ryabova V, Gevorgyan V. J. Am. Chem. Soc 2007;129:7742. [PubMed: 17539646]
- xix. For selected examples on nucleophilic attack of heteroatom at alkyne activated by Au and Ag complexes, see: (a)Gorin DJ, Davis NR, Toste FD. J. Am. Chem. Soc 2005;127:11260. [PubMed: 16089452] (b)Dubé P, Toste FD. J. Am. Chem. Soc 2006;128:12062. [PubMed: 16967944] (c)Shapiro ND, Toste ND. J. Am. Chem. Soc 2007;129:4160. [PubMed: 17371031] (d)Hashmi ASK, Rudolph M, Schymura S, Visus J, Frey W. Eur. J. Org. Chem 2006:4905. (e)Hashmi ASK, Weyrauch JP, Frey W, Bats JW. Org. Lett 2004;6:4391. [PubMed: 15524491] (f)Belting V, Krause N. Org. Lett 2006;8:4489. [PubMed: 16986932] (g)Sun J, Kozmin SA. Angew. Chem., Int. Ed 2006;45:4991. (h)Wang S, Zhang L. J. Am. Chem. Soc 2006;128:14274. [PubMed: 17076498] (i)McDonald FE, Gleason MM. J. Am. Chem. Soc 1996;118:6648. (j)McDonald FE, Burova SA, Huffman LG. Synthesis 2000:970.
- xx. For an example of a base-assisted substantial deuterium scrambling upon cycloisomerization in conjugated propargylic systems, see ref xia.
- xxi. For an example of clean 1,2-deuterium shift upon cycloisomerization, see: Sromek AW, Rubina M, Gevorgyan V. J. Am. Chem. Soc 2005;127:10500. [PubMed: 16045332]
- xxii. Deuterium labelled propargylic substrate 7 was prepared via the following sequence of steps.
- xxiii. For reviews, see: (a)Wakatsuki Y. J. Organomet. Chem 2004;689:4092. (b)Bruneau C, Dixneuf PH. Acc. Chem. Res 1999;32:311. See also: (c)McDonald FE. Chem. Eur. J 1999;5:3103.
- xxiv. For a recent example, see: Grotjahn DB, Zeng X, Cooksy AL. J. Am. Chem. Soc 2006;128:2798. [PubMed: 16506748]
- xxv. See, for example: (a)McDonald FE, Gleason MM. J. Am. Chem. Soc 1996;118:6648. (b)McDonald FE, Burova SA, Huffman LG. Synthesis 2000:970.
- xxvi. Miura T, Iwasawa N. J. Am. Chem. Soc 2002;124:518. [PubMed: 11804472]
- xxvii. Mamane V, Hannen P, Fürstner A. Chem. Eur. J 2004;10:4556.
- xxviii. Katayama H, Wada C, Taniguchi K, Ozawa F. Organometallics 2002;21:3285.
- xxix. Shirakawa E, Morita R, Tsuchimoto T, Kawakami Y. J. Am. Chem. Soc 2004;126:13614. [PubMed: 15493908]
- xxx. For recent reviews on Au-catalyzed reactions, see: (a)Hoffmann-Röder A, Krause N. Org. Biomol. Chem 2005;3:387. [PubMed: 15678171] (b)Hashmi ASK. Gold Bull 2004;37:51. For Au-catalyzed synthesis of heterocycles, see: (c)Hashmi ASK, Schwarz L, Choi J-H, Frost TM. Angew. Chem. Int. Ed 2000;39:2285. (d)Yao T, Zhang X, Larock RC. J. Am. Chem. Soc 2004;126:11164. [PubMed: 15355093] (e)Zhang L, Kozmin SA. J. Am. Chem. Soc 2005;127:6962. [PubMed: 15884934] (f)Hoffmann-Röder A, Krause N. Org. Lett 2001;3:2537. [PubMed: 11483054] (g)Sromek AW, Rubina M, Gevorgyan V. J. Am. Chem. Soc 2005;127:10500. [PubMed: 16045332] For Au-catalyzed carbocyclizations, see for example: (h)Fürstner A, Hannen P. Chem. Commun 2004:2546. (i)Shi X, Gorin DJ, Toste FD. J. Am. Chem. Soc 2005;127:5802. [PubMed: 15839674] (j)Luzung MR, Markham JP, Toste FD. J. Am. Chem. Soc 2004;126:10858. [PubMed: 15339167] (k)Zhang L, Kozmin SA. J. Am. Chem. Soc 2004;126:11806. [PubMed: 15382911] (l)Nieto-Oberhuber C, Lopez S, Echavarren AM. J. Am. Chem. Soc 2005;127:6178. [PubMed: 15853316] See also: (m)Asao N, Takahashi K, Lee S, Kasahara T, Yamamoto Y. J. Am. Chem. Soc

2002;124:12650. [PubMed: 12392398] (n)Shi Z, He C. J. Am. Chem. Soc 2004;126:5964.

[PubMed: 15137751] (o)Zhang L. J. Am. Chem. Soc 2005;127:16804. [PubMed: 16316224]

xxxi. Au(I) is most likely the active catalyst. In the case of employment of AuBr₃ as a precatalyst, the latter can be reduced into Au(I) species via various redox processes. See, ref. xxxb.

xxxii. For discussion on Au-catalyzed propargyl-allenyl prototropic isomerization, see ref. xc.

xxxiii. Control experiment indicated no proton-deuterium scrambling in the cyclized product

xxxiv. For Au-catalyzed migration of alkyl group in indole series, see: Alfonsi M, Arcadi A, Aschi M, Bianchi G, Marinelli F. J. Org. Chem 2005;70:2265. [PubMed: 15760214]

Scheme 1. Preparation of heterocycles 1

^a Isolated yields over 2 steps. ^b Isolated yields from 1'.

Scheme 2. Synthesis of 1,3-disubstituted N-fused pyrrole-containing heterocycles

^a Isolated yields. ^b 10% of catalyst was used. ^c Reaction was performed at 40°C.

Scheme 3.

Scheme 4.

9, $\text{R} = \text{H}$, 70%

11a, $\text{R} = \text{SiMe}_3$, 61%

11b, $\text{R} = \text{SnBu}_3$, 68%

11c, $\text{R} = \text{GeMe}_3$, 54%

11e, 96%

11f, $\text{R} = \text{H}$, 50%

11g, $\text{R} = \text{SiMe}_3$, 37%

11h, $\text{R} = \text{H}$, 60%

11i, $\text{R} = \text{SiMe}_3$, 57%

11j, 38%

Scheme 5.

^a Isolated yields over 2 steps.

10, R = H, 62%

12a, R = SiMe₃, 63%^b

12b, R = SnBu₃, 64%^d

12c, R = GeMe₃, 92%

12d, 62%

12e, 81%

12f, R = H, 94%

12g, R = SiMe₃, 78%

12h, R = H, 72%

12i, R = SiMe₃, 87%^c

12j, 52%

Scheme 6. Synthesis of 1,2-disubstituted N-fused pyrrole-containing heterocycles

^a Isolated yields. ^b NMR yield. ^c Yields over 2 steps. ^d AuCl was used as a catalyst.

Scheme 7.

Table 1

Catalyst optimization for synthesis of 1,3-disubstituted heterocycles

#	Catalyst	Reaction time	Yield, % ^a
1	CuI	3 hrs.	77%
2	CuCl	30 min.	83%
3	AuCl ₃	30 min.	71%
4	AuI	3 hrs	95%
5	AlCl ₃	48 hrs.	64% ^b
6	Sn(OTf) ₂	48 hrs.	31%
7	Mg(OTf) ₂	48hrs	52%
8	In(OTf) ₂	48 hrs.	33%
9	PtCl ₂	48hrs	41%
10	PdCl ₂ (PPh ₃) ₂	30 min	61%
11	Pd(OAc) ₂	30 min.	74%
12	AgBF₄	30 min.	>99%
13	AgPF₆	30 min.	>99%
14	AgSbF ₆	30 min.	52%
15	no catalyst	72 hrs	< 20 % ^c

^a GC-MS yields.^b 10 mol% of catalyst were used.^c Reaction was performed at 50°C.